Format

Send to

Choose Destination
See comment in PubMed Commons below
N Engl J Med. 2014 Oct 9;371(15):1392-406. doi: 10.1056/NEJMoa1407963. Epub 2014 Sep 19.

Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.

Collaborators (671)

Chalmers J, MacMahon S, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu LS, Mancia G, Marre M, Matthews D, Mogensen CE, Neal B, Pan CY, Patel A, Poulter N, Rodgers A, Williams B, Woodward M, Zoungas S, Billot L, Bompoint S, Li Q, Woodward M, Monaghan H, Carreras A, Zoungas S, Chalmers J, Armenis M, Naidu B, Joshi R, Woodward M, Li Q, Billot L, Bompoint S, Harrap S, Carreras A, Monaghan H, Hamet P, Guertin MR, Chretien P, Liu LS, Ma LY, Wang W, Tang RK, Zhao XM, Grobbee D, Septer-Bijleveld E, Brouwer B, Van Nierop S, Guerrero JB, Suiker A, Molenaar E, Shekary N, Wooninck S, Poulter N, Adderkin A, Thirunavukkarasu N, Bhadresa Y, Wilson A, Thiagarajah S, Michitiuc I, Gough J, Moses R, Calvert D, Nattrass N, Pape A, Webb A, McIntyre D, Diaz-Guilas S, Hancock S, Kean M, Twigg S, Caruana M, Proietto J, Jacklin C, Jerums G, MacIsaac R, Park M, van Gaal W, Russell A, Sawyer J, Davoren P, Turner F, Darnell D, Fernandez M, Darnell D, Davis T, England M, Hay L, Kim R, Siddal R, Stack P, Fulcher G, Baume R, Poynten A, Gilbert M, Rayment G, Suranyi M, Chow J, Corbould A, Cooke D, Shepherd J, Smith S, McGrath B, Hulley A, Yeap A, Jeffries W, Hoh A, Watson C, Bradshaw J, Lamberts N, Trezona B, Aguilar-Loza N, Stranks S, Taylor P, Carroll P, Duroux M, Ratcliffe M, Shone S, Clayfield M, Griek S, Nugent T, Topliss D, Park K, Ratanapongleka M, Sullivan C, Nolan C, Oon A, Adam W, Bohra S, Asher G, Clowes V, Beattie D, Grady J, Tan Y, Belanger A, Dumas R, Gauthier S, Chiasson J, Dallaire S, Doucet J, Langelier H, Hamet P, Elliott T, Inducil M, Bedard D, Leiter L, Guillemehe J, Langlois M, Bere L, Curren W, McManus R, Lachance C, St-Pierre B, McCarthy G, Ur E, Keiser P, Keiser S, Bender B, Ross S, Bolduc M, Dube F, Landcop M, Mercier L, Zhang J, Zheng Z, Wang C, Liu F, Yang H, Yan S, Tian H, Chu S, Kong Y, Qian Y, Wang G, Wang X, Chen Y, Du S, Jin G, Cui J, Jia R, Qin L, Wang H, Li Y, Zhang F, Huang Y, Lan N, Peng H, Zhang L, Zhang P, Guo B, Xing X, Chen J, Han W, Wu X, Zhang L, Han C, Yan X, Zheng L, Wang Z, Ma H, Wang L, Zhang H, Zhang H, Zhang L, C X, Pu L, Zhang T, Zhu S, Shen L, Wang G, Wang W, Xu N, Zhao B, Ge H, Ni C, Chen C, Wang T, Wang Z, Yang F, Wu K, Wang H, Jia P, Gao Y, Yang J, Wang W, Shen J, Gong X, Zhang Y, Fu H, Yuan S, Wang S, Wang Y, Lu H, Li X, Yang X, Song X, Xu Z, Bai M, Hu B, Shen RC, Su J, Zeng Z, Zhang J, Chen Y, Zhou Y, Wang W, Ning G, Liu Z, Shi Y, Tang W, Liu L, Shi J, Yu H, Bao Y, Jia W, Li C, Zhang Q, Yu D, Liu C, Yin J, Wang J, Wang W, Xiang Y, Zhang J, Mei X, Wang J, Zhou J, Li C, Gao F, Gao X, Wang J, Ding Y, Sun G, Wang F, Dong Z, Jia F, Li C, Shi F, Song Y, Li Q, Shi L, Zhao L, Zhou Y, Su S, Sun Y, Wang R, Zhang L, Zhang Q, Zhang S, Liu W, Ren L, Bian R, Chen L, Ouyang X, Wang J, Yu Y, He Y, Tang S, Zhang N, Zhang Q, Yang M, Hu L, Yu Y, Hu M, Liu H, Liu J, Wu Y, Li X, Liu S, Wu Y, Wu D, Zhang H, Shi L, Lu F, Zhao Y, Chen T, Hang L, Shu D, Patek F, Benesova R, Vlasakova Z, Brezina J, Berkova K, Komrskova M, Dohnalova L, Hund J, Jurgenson T, Kaasik U, Podar T, Moru R, Blickle J, Paris-Bockel D, Gautier A, Bonnet F, Dener C, Marechaud R, Roques M, Berkherraz A, Feron M, Marre M, Travert F, Rodier M, Bohme P, Marre M, Benamo E, Gentsch BA, Bueschges G, Kohler A, Loew A, von Schacky C, Ganz X, John F, Matschke B, Raupach P, Schaper F, Schatz U, Hanefeld M, Jermendy G, Nadas J, Koranyi L, Das S, Tandon N, Tandon R, Naik N, Prabhakaran D, Venkatesh P, Mohan V, Selvam K, Ramu M, Subramani P, Kulasegaran K, Ali M, Sethi B, Raju K, Barrett K, El-Sayed T, Gallagher B, Kavanagh L, Maguire B, Quinn U, Shortall K, Stanton A, McGrath M, Storey S, Gibney J, Burke M, Donnelly E, Khan M, Kyithar M, McCarthy A, McQuaid S, Firth R, Neary G, Connolly B, Barrett K, El-Sayed T, Gallagher B, Kavanagh L, Maguire B, Quinn U, Shortall K, Stanton A, Murphy M, Anwer Z, Chong J, Courcy M, Kelly C, Ashraf M, Barton J, Mahmood K, Perra S, Mancia G, Grassi G, Babarskiene R, Bartuseviciene S, Sirvyte R, Sirvyte R, Varoneckas G, Babarskiene R, Jeremiah H, Khir A, Soon T, Aziz N, Peng Y, Lin L, Mydin S, Chan S, Pendek R, Yeoh K, Rosales NA, Ramanathan G, Bebakar WW, Hashim DM, WanHashimi W, Yusoff R, Yusoff K, Mohd N, Mustafa M, Biermann J, Bossen W, Prins A, Janssen W, Groetelaer N, Izeboud L, Grobbee D, Grobbee D, Groetelaer N, Boonman-de Winter L, Bossers J, Van Baal CB, Van Der Smissen A, Messelink LV, Groetelaer N, Scholten M, Grobbee D, Grobbee D, Groetelaer N, Prins A, Groetelaer N, Izeboud L, Grobbee D, Grobbee D, Groetelaer N, Izeboud L, Muilwyk C, Cresswell P, Krebs J, Carswell G, Dixon P, Nesdale D, Snell H, Skeggs K, Luke R, Leikis R, Doak A, Mackenzie J, Schmid D, Spooner M, Dunn P, Forster J, Wu J, Crawford V, Johnstone A, Berry S, McEwan R, McGregor P, Scott R, CarnBennett M, James-Hartnell J, Singh J, Ward G, Barker C, Hammond M, Hills M, Baker J, Withers R, Lim-Abrahan M, Tamondong A, Resngit R, Que M, Julianes C, Panelo A, Aragon J, Calapati-Torrijos J, Macabuag-Oliva A, Wasik-Olejnik A, Oko A, Bloch C, Kawecka-Jaszcz K, Klocek M, Steuer M, Małecki M, Petriczek T, Niżankowski R, Golebowska R, Nessler J, Bandurska-Stankiewicz E, Tarasiewicz U, Dworzanski W, Bezezicka A, Ciesielska M, Górnikiewicz-Brzezicka B, Pyka L, Dmitrova T, Efremovtseva M, Kobalava Z, Moiseev V, Fremovceva A, Babenko A, Zalevskaya A, Volkva A, Conrady A, Sviryaev Y, Dorofeikov V, Shlyakhto E, Zvartau N, Sojka G, Nociar J, Belesova K, Cunningham M, Nisbet C, Heller S, Gandhi R, Hardy D, Hall E, Drake C, Balakrishnan K, Byrne K, Caddick H, Collins J, Cruickshank K, Dunkerley J, Holland M, Jaison B, Kaur R, Patel D, Ritchie J, Vinod C, Soran H, Kwok S, Jones K, Woodcock M, Furnace J, Henderson J, MacLeod M, Brela J, Bryan L, Donley P, Jackson S, Meakin L, Bunker J, Callister W, Coghlan C, James R, Lanzon-Miller H, Mackay J, Paciello F, Thom S, Henry-Mitchell N, Sever P, Chapman N, Williams H, Akunuri S, Gupta A, Robbins S, Murphy C, Coghlan P, Wallis E, Gadhvi K, King L, Jungee N, Begg A, Drummond R, Fisher M, McKenzie J, Peterson A, Shankarnarayah S, Vora J, Westwell F, Stoddern J, Ahulwalia R, Begg A, Fisher M, Matthews D, Devers M, Kelly J, McIntyre E, Welsh B, McMahon J, Howat I, Brown R, Haynes R, Lip G, Partridge J, Cooley A, Apostolakis S, Ghattas A, Kasmeridis C, Kaur J, Christos D, Carr S, Godfrey D, Millward A, Taggart M, Watt M, Stokes J, Greatrex J, McLenaghan A, Reckless J, Robinson A, Stirling C, Thomas J, Higgs E, Ward A, Groombridge F, Allen K, Nairn L, Sutton J, Simpson H, Arain T, Young D, Baksi A, Nicol E, Wilson P, Cunningham M, Heller S, Hudson S, Nisbet C, Gandhi R, Elliot J, Fox C, Campey L, Hall K, Hollway M, James L, Nayani G, Alarcon M, Farmer J, Gopinath A, James D, Patel V, Saravanan P, Selvanonj S, Nair R, Horrocks P, Mahto R, Parsons P.

Abstract

BACKGROUND:

In the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial, the combination of perindopril and indapamide reduced mortality among patients with type 2 diabetes, but intensive glucose control, targeting a glycated hemoglobin level of less than 6.5%, did not. We now report results of the 6-year post-trial follow-up.

METHODS:

We invited surviving participants, who had previously been assigned to perindopril-indapamide or placebo and to intensive or standard glucose control (with the glucose-control comparison extending for an additional 6 months), to participate in a post-trial follow-up evaluation. The primary end points were death from any cause and major macrovascular events.

RESULTS:

The baseline characteristics were similar among the 11,140 patients who originally underwent randomization and the 8494 patients who participated in the post-trial follow-up for a median of 5.9 years (blood-pressure-lowering comparison) or 5.4 years (glucose-control comparison). Between-group differences in blood pressure and glycated hemoglobin levels during the trial were no longer evident by the first post-trial visit. The reductions in the risk of death from any cause and of death from cardiovascular causes that had been observed in the group receiving active blood-pressure-lowering treatment during the trial were attenuated but significant at the end of the post-trial follow-up; the hazard ratios were 0.91 (95% confidence interval [CI], 0.84 to 0.99; P=0.03) and 0.88 (95% CI, 0.77 to 0.99; P=0.04), respectively. No differences were observed during follow-up in the risk of death from any cause or major macrovascular events between the intensive-glucose-control group and the standard-glucose-control group; the hazard ratios were 1.00 (95% CI, 0.92 to 1.08) and 1.00 (95% CI, 0.92 to 1.08), respectively.

CONCLUSIONS:

The benefits with respect to mortality that had been observed among patients originally assigned to blood-pressure-lowering therapy were attenuated but still evident at the end of follow-up. There was no evidence that intensive glucose control during the trial led to long-term benefits with respect to mortality or macrovascular events. (Funded by the National Health and Medical Research Council of Australia and others; ADVANCE-ON ClinicalTrials.gov number, NCT00949286.).

PMID:
25234206
DOI:
10.1056/NEJMoa1407963
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center